华熙生物回应争议：透明质酸业务并未承压 重组胶原蛋白尚需验证

Core Viewpoint - The ongoing debate regarding "recombinant collagen" has raised significant industry and market attention, with the company emphasizing the need to correct misleading perceptions in the capital market that deviate from scientific and industrial fundamentals [1][2]. Group 1: Company Position on Recombinant Collagen - The company argues that recombinant collagen is a minor branch of collagen research and industrial transformation, with the main advancements in protein research being led by life science institutions and pharmaceutical companies, not cosmetic firms [1][2]. - The company highlights that there is currently no international approval for medical devices based on recombinant collagen, indicating the need for longer observation periods in this field [2]. - The company asserts that the growth of its hyaluronic acid business remains stable, with an annual growth rate exceeding 10%, while the recombinant collagen market lacks a mature international market comparable to hyaluronic acid [3][4]. Group 2: Market Dynamics and Performance - The company clarifies that its performance adjustments are not solely due to the rise of recombinant collagen, as its hyaluronic acid business continues to grow, particularly in the pharmaceutical-grade and overseas export segments, which have seen over 20% growth [3][4]. - The decline in overall performance is attributed to a downturn in consumer goods and one-time asset impairment losses, rather than the emergence of recombinant collagen as a competitive force [4]. - The company emphasizes that the concept of "recombinant collagen" is often misrepresented, as it does not meet the academic standards required for biological functionality [5][6]. Group 3: Industry Ecosystem and Communication - The company stresses the importance of establishing a credible foundation for domestic brands, which should not rely on the misuse of academic terms and concepts that mislead consumers [7]. - The company calls for a collaborative effort among industry participants, regulatory bodies, and media to enhance understanding and improve the overall ecosystem, ensuring that scientific and industrial developments are accurately represented [9]. - The company plans to strengthen professional communication with the capital market, recognizing the need for better understanding of the biological sciences among analysts and investors [8].